8-KRegulation FDExhibits & Filings

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Jun 22, 2026)

Filed June 22, 2026For Securities:ABBV

Summary

AbbVie Inc. (ABBV) announced a significant strategic move via a joint press release with Apogee Therapeutics, Inc. on June 22, 2026, detailing a definitive agreement for AbbVie to acquire Apogee. This acquisition signals AbbVie's commitment to expanding its pipeline and therapeutic offerings. While specific financial terms of the deal are not disclosed in this 8-K, the accompanying investor presentation (Exhibit 99.2) likely elaborates on the strategic rationale and potential financial impact. Investors should note that this filing is primarily for Regulation FD disclosure, providing public access to the press release and presentation materials. The report highlights forward-looking statements concerning the benefits of the acquisition, integration plans, and the potential of Apogee's pipeline assets, including zumilokibart (APG777). However, the company also outlines numerous risks and uncertainties associated with the transaction, common in M&A activities, which could materially affect future results.

Key Highlights

  • 1AbbVie Inc. has entered into a definitive agreement to acquire Apogee Therapeutics, Inc.
  • 2The announcement was made through a joint press release and accompanying investor presentation on June 22, 2026.
  • 3The acquisition aims to enhance AbbVie's pipeline and therapeutic capabilities.
  • 4Forward-looking statements mention potential accretion to AbbVie's adjusted diluted earnings per share beginning in 2032.
  • 5Key Apogee pipeline assets, including zumilokibart (APG777), are highlighted as potential drivers of future value.
  • 6The filing includes detailed discussions of risks and uncertainties inherent in the acquisition and integration process.
  • 7This report primarily serves as a Regulation FD disclosure, incorporating exhibits that contain transaction details.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly disclose AbbVie Inc.'s definitive agreement to acquire Apogee Therapeutics, Inc. under Regulation FD. It includes a joint press release and an investor presentation that provide details about the transaction to all investors simultaneously.

The filing specifically mentions zumilabart (APG777) as a key pipeline asset of Apogee. Other pipeline assets of Apogee are also noted as being part of the acquisition, suggesting a broader strategic intent beyond a single drug candidate.

Forward-looking statements in the filing suggest potential accretion to AbbVie's adjusted diluted earnings per share beginning in 2032. The investor presentation (Exhibit 99.2) is likely to provide more detailed financial projections and rationale for the acquisition.

The filing outlines numerous risks, including potential termination of the merger agreement, failure to obtain necessary approvals, integration challenges, disruption to current business operations, adverse effects on stock price, retention of key personnel, and uncertainties regarding the success and efficacy of Apogee's pipeline assets in clinical trials.